Metrics as of 10/13/2026, 02:29 PM (Berlin time), refresh in progress.
ArriVent BioPharma Stock
ArriVent BioPharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Zhengbin Yao
- Employees
- 77
- Market cap
- $773 M
- IPO
- 26/01/2024
- Web
- arrivent.com
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in…
ArriVent BioPharma stock: price history
1D
+0.7%
1W
+9.9%
1M
-42.8%
6M
-40.0%
YTD
-17.6%
1Y
-20.7%
2Y
-41.3%
5Y
–
10Y
–
Next earnings date
Next earnings date
16/11/2026 (in 30 days)
Volatility around earnings
~16% weaker price swings than usual
Ask the agents about ArriVent BioPharma
Analyst assessment of ArriVent BioPharma
PRICE TARGET LOW
US$18.00
CONSENSUS
US$22.00
MEDIAN
US$18.00
PRICE TARGET HIGH
US$29.00
0
STRONG BUY
9
BUY
0
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 08/10/2026
ArriVent BioPharma stock metrics
P/E
-4.51
P/B
2.15
EV/EBITDA
-3.78
RETURN ON EQUITY
-13.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
63.9%
FLOAT SHARES
29,777,214
AVG. DAILY VOLUME (30D)
1,482,187
Institutional holders
Comparable stocks
Frequently asked questions about ArriVent BioPharma stock
What does ArriVent BioPharma do?
ArriVent BioPharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Zhengbin Yao, the company employs around 77 people.
The IPO was on 26/01/2024; the stock trades on NASDAQ under the ticker AVBP.
What do analysts say about ArriVent BioPharma stock?
9 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$22.00, ranging from US$18.00 to US$29.00, with a median of US$18.00.
This is an external assessment, not a statement by Market Jury.
When does ArriVent BioPharma report next?
The next earnings date is 16/11/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does ArriVent BioPharma pay a dividend?
No, ArriVent BioPharma currently does not pay a dividend.
Which stocks are comparable to ArriVent BioPharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get ArriVent BioPharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess ArriVent BioPharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.